Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

pembrolizumab 2tocilizumab 1poly ICLC 1flt3 ligand protein 1cemiplimab 1SUB1 protein, human 1Radiotherapy 1Radiation 1Interleukin-2 1Capecitabine 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × tocilizumab × Breast × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡